Indolizines as kinase protein inhibitors
CA 2466243 A1 · Owner: Aventis Pharma S.A. · Inventors: Venot, Corinne; Nemecek, Conception; Majid, Tahir Nadeem
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention concerns compounds of general formula (I): in which: R1 represents hydrogen, R4, -C(=Y)-NHR4, -SO2NHR4 -C(=Z1)-R4, -SO2-R4 or -C(=Z1)-, OR4; R2 represents hydrogen cyano, halogen or -C~C-R5;R3 represents hydrogen acyl, alkoxycarbonyl, alkyl, aroyl, aryl aryloxycarbonyl, carboxy, cycloalkenyl cycloalkyl, heteroaroyl, heteroaryl, heterocycloalkyl or -C(=O)- NY1Y2; R4 represents optionally substituted alkyl cycloalkyl, cycloalkenyl ,heterocycloalkyl aryl or heteroaryl R5 represents hydrogen or alkyl;R6 represents alkyl, acyl, alkoxycarbonyl alkylsulfonyl, aryl, arylsulfonyl, aroyl cycloalkyl, cycloalkenyl, heteroaryl, heteroarylsulfonyl heteroaroyl , and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 17, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 17, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 17, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.